Search ISRG
INTUITIVE SURGICAL INC
Nasdaq · CIK 1035267
Last close391.95
Daily change-9.29 (-2.32%)
10 Years gain+391.34%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
ISRG · STANDARD
SIC 3842 · Orthopedic, Prosthetic & Surgical Appliances & Supplies · Fiscal year end 1231
Fundamental
73.1Momentum
73.2Acceleration
73.2Confidence
86.0Annual Revenue19
Quarterly Revenue84
Annual CFO19
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth21.5 / 25
Quality15.7 / 25
Capital Efficiency17.3 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators3.7 / 5
Signals
Gross margin expansionGross margin improved by 0.1332 percentage points.
Operating leverageOperating margin improved by 4.6346 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Share count reductionDiluted share count declined 2.0022%.
Strong operating leverageOperating income is growing faster than revenue while operating margin expands.
Key Metrics
Revenue Growth TTM29.49%OK
Revenue CAGR 3Y17.39%OK
Gross Margin66.66%OK
Operating Margin31.39%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC21.4%OK
Incremental Operating Margin 3Y37.2%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-2%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $10.06B | $6.64B | $2.95B | $3.03B | $2.49B | 66% | 29.27% | 24.75% | 21.05% | 362.7M |
| 2025 FY Dec 31, 2024 | $8.35B | $5.63B | $2.35B | $2.42B | $1.30B | 67.46% | 28.12% | 15.61% | 20.03% | 362M |
| 2025 FY Dec 31, 2023 | $7.12B | $4.73B | $1.77B | $1.81B | $749.60M | 66.39% | 24.8% | 10.52% | 21.84% | 357.4M |
| 2024 FY Dec 31, 2022 | $6.22B | $4.20B | $1.58B | $1.49B | $958.40M | 67.44% | 25.35% | 15.4% | 18.05% | 362M |
| 2023 FY Dec 31, 2021 | $5.71B | $3.96B | $1.82B | $2.09B | $1.75B | 69.32% | 31.89% | 30.65% | 27.03% | 365.8M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $10.61B | sum latest 4 fiscal quarters Revenue | OK | 0001035267-26-000058, 0001035267-25-000209 |
| Revenue Growth TTM | 29.49% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001035267-26-000058, 0001035267-25-000209 |
| Revenue CAGR 3Y | 17.39% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001035267-26-000010 |
| Revenue CAGR 5Y | 18.22% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001035267-26-000010 |
| Gross Profit CAGR 3Y | 16.55% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001035267-26-000010 |
| Operating Income Growth | 51.92% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001035267-26-000058, 0001035267-25-000209 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 66.66% | Gross Profit / Revenue | OK | 0001035267-26-000058, 0001035267-25-000209 |
| Operating Margin | 31.39% | Operating Income / Revenue | OK | 0001035267-26-000058, 0001035267-25-000209 |
| ROIC | 21.4% | NOPAT / Average Invested Capital | OK | 0001035267-26-000058, 0001035267-25-000209 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001035267-26-000058 |
| Current Ratio | 4.96x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $29.69 | Revenue / Diluted Shares | OK | 0001035267-26-000058, 0001035267-25-000209 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |